OLX 70X
Alternative Names: OLX-70XLatest Information Update: 25 May 2022
At a glance
- Originator OliX Pharmaceuticals
- Class Amides; Amino sugars; Drug conjugates; Hepatoprotectants; Pyrrolidines; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Liver disorders
Most Recent Events
- 25 May 2022 OLX 70X is available for licensing as of 25 May 2022. https://www.olixpharma.com/eng/
- 14 May 2022 OliX Pharmaceuticals has patents protection for novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof in Issued in Korea, Europe, Japan, Australia and China
- 11 May 2022 Early research in Liver disorders in South Korea (SC) (OliX Pharmaceuticals pipeline; May 2022)